It might be the latest version of a long-term strategic policy approach, but stakeholders need to ask themselves a critical question. Are they willing to trade a bridging fund and process changes for a few health technologies, based on the promise it could accelerate access, in return for a disinvestment framework and deprioritising most new therapies?
Stakeholders deserve clarity on the strategic objective before this process gets underway
November 25, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Moderna taps Salesforce to unify global commercial operations
April 30, 2026 - - Latest News -
How do we know the HTA institution loves patients? Because they use a love heart emoji
April 30, 2026 - - Latest News -
Australian company secures capital raise to advance amsulostat trials and strengthen pipeline
April 29, 2026 - - Latest News -
Australia urged to strengthen sunscreen literacy and label clarity
April 29, 2026 - -
'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'
April 29, 2026 - - Latest News -
We need to say it again, just in case, that this advice is about ministerial choices and not conditions
April 29, 2026 - - Latest News -
Families welcome cancer drug progress but remain cautious over timely access
April 28, 2026 - - Latest News
